Comparison of Commercial Genetic-Testing Services in Korea with 23andMe Service

Abstract EN

Introduction.

Genetic testing services for disease prediction, drug responses, and traits are commercially available by several companies in Korea.

However, there has been no evaluation study for the accuracy and usefulness of these services.

We aimed to compare two genetic testing services popular in Korea with 23andMe service in the United States.

Materials and Methods.

We compared the results of two persons (one man and one woman) serviced by Hellogene Platinum (Theragen Bio Institute), DNAGPS Optimus (DNAlink), and 23andMe service.

Results.

Among 3 services, there were differences in the estimation of relative risks for the same disease.

For lung cancer, the range of relative risk was from 0.9 to 2.09.

These differences were thought to be due to the differences of applied single nucleotide polymorphisms (SNPs) in each service for the calculation of risk.

Also, the algorithm and population database would have influence on the estimation of relative disease risks.

The concordance rate of SNP calls between DNAGPS Optimus and 23andMe services was 100% (30/30).

Conclusions.

Our study showed differences in disease risk estimations among three services, although they gave good concordance rate for SNP calls.

We realized that the genetic services need further evaluation and standardization, especially in disease risk estimation algorithm.